Nasdaq
$1.42▲ 1.10%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $7.3MShares out 5.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 10.13After-hours26.10.14 05:064Ownership#●●●
MetaVia Inc.
Insider Sarah Kaplan Browne of MetaVia Inc. reported a change in beneficial ownership of securities as of October 12, 2026. This filing formalizes the insider's equity transaction via Form 4.…more
$1.42+1.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13After-hours26.10.14 05:053Ownership
MetaVia Inc.
Sarah Kaplan Browne, an officer, director, or stockholder of MetaVia Inc., has filed a Power of Attorney authorizing designated representatives to handle SEC filings and EDGAR account management on her behalf. Executed on October 3, 2026, this document grants the appointed attorneys-in-fact full authority to prepare and submit required filings under the Securities Exchange Act.…more
$1.42+1.10%vs prev closeView filingShare - 10.13Pre-market26.10.13 21:358-KKey event
MetaVia Inc.
MetaVia Inc. appointed Sarah Kaplan Browne, M.D., as Chief Medical Officer, effective October 12, 2026. Dr. Browne will lead the clinical development strategy for the company's cardiometabolic pipeline, including the upcoming Phase 1 Part 3 data readout for DA-1726.…more
$1.42+1.10%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.9Pre-market26.09.09 21:07#●●●#●●●
MetaVia Announces Preclinical Results for DA-1726
MetaVia reported that its DA-1726 candidate showed high exposure in adipose tissue and prolonged retention through 144 hours in preclinical studies. Topline data for the 16-week study is expected in Q4, with 24-week results anticipated in Q1 2027.…more
$1.42+1.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga